These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36431342)

  • 21. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
    Nicolò M; Ferro Desideri L; Bassetti M; Traverso CE
    Int Ophthalmol; 2021 Feb; 41(2):719-725. PubMed ID: 32946004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.
    Chowdhury MS; Rathod J; Gernsheimer J
    Acad Emerg Med; 2020 Jun; 27(6):493-504. PubMed ID: 32359203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.
    De Luca P; Scarpa A; De Bonis E; Cavaliere M; Viola P; Gioacchini FM; Ralli M; Ettore C; Claudia C
    Am J Otolaryngol; 2021; 42(5):102640. PubMed ID: 33780902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
    Spila Alegiani S; Crisafulli S; Giorgi Rossi P; Mancuso P; Salvarani C; Atzeni F; Gini R; Kirchmayer U; Belleudi V; Kurotschka PK; Leoni O; Ludergnani M; Ferroni E; Baracco S; Massari M; Trifirò G;
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI25-SI36. PubMed ID: 33856453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Chen Z; Liu A; Cheng Y; Wang X; Xu X; Huang J; Ma Y; Gao M; Huang C
    BMC Infect Dis; 2021 Aug; 21(1):805. PubMed ID: 34384388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials.
    Ebina-Shibuya R; Namkoong H; Horita N; Kato H; Hara Y; Kobayashi N; Kaneko T
    J Thorac Dis; 2021 Jan; 13(1):202-212. PubMed ID: 33569200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis.
    Tleyjeh IM; Kashour Z; AlDosary O; Riaz M; Tlayjeh H; Garbati MA; Tleyjeh R; Al-Mallah MH; Sohail MR; Gerberi D; Bin Abdulhak AA; Giudicessi JR; Ackerman MJ; Kashour T
    Mayo Clin Proc Innov Qual Outcomes; 2021 Feb; 5(1):137-150. PubMed ID: 33163895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
    Nadeem U; Raafey M; Kim G; Treger J; Pytel P; N Husain A; Schulte JJ
    Am J Clin Pathol; 2021 May; 155(6):793-801. PubMed ID: 33316045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis and clinical assessment: an updated meta-analysis of randomized trials.
    Han X; Shi W; Yang Y
    J Thorac Dis; 2024 May; 16(5):2983-2993. PubMed ID: 38883686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients.
    Askarian F; Firoozi Z; Ebadollahi-Natanzi A; Bahrami S; Rahimi HR
    Toxicol Res; 2022 Apr; 38(2):137-148. PubMed ID: 34306523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effectiveness of antimalarial drugs in rheumatic diseases.
    Aviña-Zubieta JA; Galindo-Rodriguez G; Newman S; Suarez-Almazor ME; Russell AS
    Ann Rheum Dis; 1998 Oct; 57(10):582-7. PubMed ID: 9893568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
    Saint-Gerons DM; Tabarés-Seisdedos R
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.
    Richard SA; Kampo S; Hechavarria ME; Sackey M; Buunaaim ADB; Kuugbee ED; Anabah TW
    J Immunol Res; 2020; 2020():4582612. PubMed ID: 33062720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review.
    Chen L; Chen H; Dong S; Huang W; Chen L; Wei Y; Shi L; Li J; Zhu F; Zhu Z; Wang Y; Lv X; Yu X; Li H; Wei W; Zhang K; Zhu L; Qu C; Hong J; Hu C; Dong J; Qi R; Lu D; Wang H; Peng S; Hao G
    Function (Oxf); 2020; 1(2):zqaa012. PubMed ID: 38626250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.
    Acharya Y; Sayed A
    Ther Adv Infect Dis; 2020; 7():2049936120947517. PubMed ID: 32821381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
    Fatima U; Rizvi SSA; Fatima S; Hassan MI
    J Interferon Cytokine Res; 2020 Oct; 40(10):469-471. PubMed ID: 32881593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.
    Badraoui R; Adnan M; Bardakci F; Alreshidi MM
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33525415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.